Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0W64U)

Drug Name

Dihydropyridines Drug Info

Synonyms

1,2-dihydropyridine; UNII-YA306KG67U; 22694-45-7; YA306KG67U; Pyridine, 1,2-dihydro-; AC1L8RRH; CTK1A1117; MMWRGWQTAMNAFC-UHFFFAOYSA-N; AKOS006352484; 27183-EP2311806A2; 27183-EP2308562A2; 27183-EP2301911A1; 27183-EP2292593A2; 27183-EP2314575A1; 27183-EP2295427A1; 27183-EP2270010A1; 27183-EP2269990A1; 27617-EP2270006A1; 27183-EP2371811A2; 27183-EP2308510A1; 27183-EP2295426A1; 27183-EP2275404A1; 27617-EP2314587A1; 27183-EP2292611A1; 27183-EP2284149A1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 407038
CAS Number: CAS 22694-45-7
TTD Drug ID: DM0W64U

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated L-type calcium channel (L-CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[2]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[3]
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[4]
Otilonium bromide	DM05968	Gastric motility disorder	DA21	Approved	[5]
Levamlodipine	DM92S6N	Hypertension	BA00-BA04	Phase 4	[6]
Cilnidipine	DM1975O	High blood pressure	BA00	Phase 3	[7]
Pinaverium bromide	DM7OSHC	Irritable bowel syndrome	DD91.0	Phase 3	[5]
MEM-1003	DMYZU6G	Bipolar disorder	6A60	Phase 2a	[8]
Gallopamil	DMXBR27	Asthma	CA23	Phase 2	[9]
BAY-Y-5959	DMLO18H	Cardiovascular disease	BA00-BE2Z	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated L-type calcium channel (L-CaC)	TTXHYV6	NOUNIPROTAC	Blocker	[1]

------------------------------------------------------------------------------------

References

1	Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4	Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95.
5	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
6	Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4.
7	N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000.
8	Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73.
9	Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15.
10	Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6.